Literature DB >> 33502327

Tui Na for Chronic Nonspecific Low Back Pain: Protocol for a Systematic Review and Meta-analysis.

Juan Yang1, Jeffrey S Brault2, Mark A Jensen2, Alexander Do1, Qingyu Ma3, Xuan Zhou3, Longbin Shen4, Canghuan Zhao4, Kwok Chee Philip Cheong5, Kejie He4, Yu Guo3, Zhuoming Chen4, Shujie Tang6, Yong Tang6, Celia Ia Choo Tan7, Jiaxu Chen3, Brent A Bauer1.   

Abstract

BACKGROUND: Chronic nonspecific low back pain (CNLBP) is one of the most common complex pain conditions, and it is strongly associated with high rates of disability. Even though several studies on Tui na for CNLBP have been reported, to our knowledge there has been no systematic review of the currently available publications.
OBJECTIVE: This study aims to develop a protocol for a systematic review and meta-analysis that will evaluate the effectiveness and safety of Tui na therapy for patients with CNLBP.
METHODS: An electronic literature search of PubMed, Embase, MEDLINE, Cochrane Library, Springer, Scopus, World Health Organization International Clinical Trials Registry Platform, Physiotherapy Evidence Database (PEDro), Clarivate Analytics, and Chinese biomedical databases (the China National Knowledge Infrastructure, Wan-fang database, Chinese Scientific Journals Database, and Chinese Biomedical Literature Databases) will be conducted. Studies will be screened by two reviewers independently based on titles and abstracts, followed by a full-text reading with eligibility criteria. Randomized controlled trials involving Tui na for patients with CNLBP will be reviewed. The primary outcomes of the study are improvement of pain, analgesic medication reduction, improvement of functional disability, and degree of satisfaction with the intervention. A secondary outcome is any adverse event of Tui na intervention. Methodological quality and risk of bias will be assessed with the Cochrane Collaboration Risk of Bias Tool. If studies are sufficient, a meta-analysis of the effectiveness will be performed. If possible, we will evaluate publication bias using funnel plots. If substantial heterogeneity between studies is present, and there are sufficient studies, subgroup analyses will be conducted to explain the study findings.
RESULTS: The review database searches will be initiated in December 2020, with findings expected by January 2021.
CONCLUSIONS: This protocol will establish a framework of a high-quality literature synthesis on the impact of Tui na treatment in patients with CNLBP. The proposed review will determine whether Tui na is effective and safe for CNLBP patients. TRIAL REGISTRATION: PROSPERO CRD42020166731; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=166731. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/20615. ©Juan Yang, Jeffrey S. Brault, Mark A. Jensen, Alexander Do, Qingyu Ma, Xuan Zhou, Longbin Shen, Canghuan Zhao, Kwok Chee Philip Cheong, Kejie He, Yu Guo, Zhuoming Chen, Shujie Tang, Yong Tang, Celia Ia Choo Tan, Jiaxu Chen, Brent A. Bauer. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 27.01.2021.

Entities:  

Keywords:  Tui na; Tuina; low back pain; protocol; systematic review

Year:  2021        PMID: 33502327      PMCID: PMC7875686          DOI: 10.2196/20615

Source DB:  PubMed          Journal:  JMIR Res Protoc        ISSN: 1929-0748


  20 in total

1.  A meta-analysis of massage therapy research.

Authors:  Christopher A Moyer; James Rounds; James W Hannum
Journal:  Psychol Bull       Date:  2004-01       Impact factor: 17.737

2.  Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

Authors:  Alice P Chen; Ann Setser; Milan J Anadkat; Jonathan Cotliar; Elise A Olsen; Benjamin C Garden; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2012-04-11       Impact factor: 11.527

Review 3.  Non-specific low back pain.

Authors:  Federico Balagué; Anne F Mannion; Ferran Pellisé; Christine Cedraschi
Journal:  Lancet       Date:  2011-10-06       Impact factor: 79.321

Review 4.  An updated overview of clinical guidelines for the management of non-specific low back pain in primary care.

Authors:  Bart W Koes; Maurits van Tulder; Chung-Wei Christine Lin; Luciana G Macedo; James McAuley; Chris Maher
Journal:  Eur Spine J       Date:  2010-07-03       Impact factor: 3.134

Review 5.  What low back pain is and why we need to pay attention.

Authors:  Jan Hartvigsen; Mark J Hancock; Alice Kongsted; Quinette Louw; Manuela L Ferreira; Stéphane Genevay; Damian Hoy; Jaro Karppinen; Glenn Pransky; Joachim Sieper; Rob J Smeets; Martin Underwood
Journal:  Lancet       Date:  2018-03-21       Impact factor: 79.321

Review 6.  Guideline recommendations on the pharmacological management of non-specific low back pain in primary care - is there a need to change?

Authors:  Marco Schreijenberg; Bart W Koes; Chung-Wei Christine Lin
Journal:  Expert Rev Clin Pharmacol       Date:  2019-01-16       Impact factor: 5.045

7.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.

Authors:  Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  BMJ       Date:  2015-01-02

8.  Methodology in conducting a systematic review of systematic reviews of healthcare interventions.

Authors:  Valerie Smith; Declan Devane; Cecily M Begley; Mike Clarke
Journal:  BMC Med Res Methodol       Date:  2011-02-03       Impact factor: 4.615

Review 9.  Prevalence of chronic low back pain: systematic review.

Authors:  Rodrigo Dalke Meucci; Anaclaudia Gastal Fassa; Neice Muller Xavier Faria
Journal:  Rev Saude Publica       Date:  2015-10-20       Impact factor: 2.106

10.  Chinese massage combined with herbal ointment for athletes with nonspecific low back pain: a randomized controlled trial.

Authors:  Ling Jun Kong; Min Fang; Hong Sheng Zhan; Wei An Yuan; Ji Ming Tao; Gao Wei Qi; Ying Wu Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.